Jordan’s exports of pharmaceutical preparations (human medicines) grew by 6% from the beginning of this year through the end of August, compared to the same period last year, driven by several factors—chief among them, the royal support and high-level attention given to the sector.
According to Dr. Fadi Al-Atrash, representative of the therapeutic industries and medical supplies sector at the Jordan Chamber of Industry, the Kingdom’s pharmaceutical exports reached 398 million dinars by the end of August 2025, up from 376 million dinars during the same period last year, based on data from the Department of Statistics.
Al-Atrash told the Jordan News Agency (Petra) that pharmaceutical exports have maintained their strong performance since the beginning of the year, supported by multiple pillars, foremost of which is the continuous support and interest from His Majesty King Abdullah II. He highlighted the King’s ongoing efforts to help open new export markets and create opportunities for Jordanian companies, recalling His Majesty’s recent visits to Kazakhstan and Uzbekistan, which yielded tangible results in this regard.
He added that Jordan’s pharmaceutical products have entered new export markets, contributing to the sector’s overall growth. This has been accompanied by the registration of new, innovative products that meet market needs, in addition to the expansion of markets in neighboring countries, particularly Iraq and Saudi Arabia.
Al-Atrash noted that the strong reputation and high quality of Jordanian medicines have enhanced export growth, as demand for Jordanian pharmaceutical products continues to rise. He also commended the efforts of the Jordan Food and Drug Administration (JFDA) in preparing local manufacturers and helping them meet international standards through Good Manufacturing Practices (GMP), which has improved product quality and boosted competitiveness abroad.
He explained that the human pharmaceuticals industry represents 85% of the overall therapeutic industries and medical supplies sector in Jordan. The industry currently includes 27 manufacturing facilities across the Kingdom, with a registered capital of around 350 million dinars, and provides approximately 10,000 direct and indirect jobs, 35% of which are held by women.
Al-Atrash, who also serves as the CEO and Board Member of Amman Pharmaceutical Industries, emphasized that Jordanian pharmaceutical exports now reach over 85 markets worldwide, including Saudi Arabia, Iraq, the UAE, Algeria, Yemen, and the United States.
He concluded by noting that the human pharmaceuticals industry is a key pillar of Jordan’s Economic Modernization Vision, supporting the growth of high-value export industries, as it constitutes about 5% of Jordan’s total industrial exports.
